Epigenetic modifiers for use in cellular immunotherapy
AssigneeViracta Therapeutics, Inc.
InventorsMarshelle WARREN, Preston DANIELS
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions useful for augmenting cell-based immunotherapies. The augmented cell-based immunotherapies can be used to treat individuals with cancer and chronic viral infections.
Claims101
A method for augmenting a cell-based immunotherapy comprising contacting a cell-based immunotherapy in vitro with an HDAC inhibitor (HDACi), wherein the HDACi comprises nanatinostat (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide).
A method of adoptive cell immunotherapy comprising:
- a) contacting a cell-based immunotherapy with an HDAC inhibitor (HDACi), wherein the HDACi comprises nanatinostat (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide);
- and
- b) administering the cell-based immunotherapy to an individual afflicted with a disease.
A method of treating human immunodeficiency (HIV) infection in an individual comprising:
- administering to an individual with an HIV infection an effective amount of nanatinostat, wherein the individual with an HIV infection has an HIV viral load of less than 1000 copies of HIV RNA per milliliter of blood.
A method for treating an individual with a latent viral infection comprising:
- a) administering to an individual with the latent viral infection a first histone deactylase inhibitor (HDACi);
- b) contacting a cell-based immunotherapy in vitro with a second HDACi, wherein the second HDACi comprises nanatinostat (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide);
- and
- c) administering the cell-based immunotherapy to the individual with the latent viral infection.
A method for treating an individual with a latent viral infection comprising:
- a) administering to an individual with the latent viral infection a first histone deactylase inhibitor (HDACi), wherein the first HDACi comprises nanatinostat (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide));
- b) contacting a cell-based immunotherapy in vitro with a second HDACi;
- and
- c) administering the cell-based immunotherapy to the individual with the latent viral infection.
Dependencies are inferred from the claim text.